A charging device for a physiological signal transmitter is disclosed. The charging device includes a transmitter placing seat, and a controlling module controlling an operation between the charging device and the physiological signal transmitter in a safe state. When the physiological signal transmitter is at the predetermined position, the locking portion unlocks the operating portion to perform one of driving the second electrical connecting port to move from the first position to the second position to electrically connect to the first electrical connecting port and driving the second electrical connecting port to move from the second position to the first position to electrically disconnect to the first electrical connecting port.

A charging device for a physiological signal transmitter used to receive a physiological signal from the subcutaneous tissue of a living body and having a first electrical connecting port is disclosed. The charging device includes a transmitter placing seat and a charging module. The transmitter placing seat includes a bearing surface for placing the physiological signal transmitter and an opening configured to align with the first electrical connection port of the physiological signal transmitter. The charging module includes a second electrical connecting port, a third electrical connecting port, a circuit assembly and a control module. The second electrical connecting port is disposed in the opening, and driven to move between a first position and a second position. The third electrical connecting port connects to a power source.

A medical remote controller device is disclosed. The device includes a display and at least one input switch dedicated to bolus delivery wherein a bolus delivery is programmed when the input switch receives an input and wherein the number of inputs received by the input switch determines the amount of bolus to be delivered.

Electronic modules for attachment to a drug delivery device include delivery status sensing means (21, 22) for monitoring a delivery status of the device, a status indicator (25) with an indicator element controllable to indicate a delivery or module status, and a status indicator controller (23), which generates an indicator control signal on behalf of the status indicator element, which in turn produces a status signal. The indicator control signal has an amplitude varying monotonically in time between a minimum value and a maximum value in a first interval of a base cycle, and between the maximum value and the minimum value in a second interval of the base cycle. In at least one of the first and the second interval, the mean value of the indicator control signal is below the average of the maximum and the minimum values of the indicator control signal to realize increased energy savings.

A method of administering insulin includes receiving blood glucose measurements of a patient at a data processing device from a glucometer. Each blood glucose measurement is separated by a time interval and includes a blood glucose time associated with a time of measuring the blood glucose measurement. The method also includes receiving patient information at the data processing device and selecting a subcutaneous insulin treatment for tube-fed patients from a collection of subcutaneous insulin treatments. The selection is based on the blood glucose measurements and the patient information. The subcutaneous insulin treatment program for tube-fed patients determines recommended insulin doses based on the blood glucose times. The method also includes executing, using the data processing device, the selected subcutaneous insulin treatment.

Methods of insulin delivery and an insulin pump are disclosed.

The prefilled syringe according to the present disclosure includes: a liquid medicine; a barrel including a cylindrical barrel body section that contains the liquid medicine, and a nozzle section that is provided on a distal end side of the barrel body section and configured to discharge the liquid medicine, the barrel being provided with a proximal end opening on a proximal end section of the barrel body section; a cap configured to seal a distal end opening provided on a distal end section of the nozzle section; a gasket configured to slide on an inner circumferential surface of the barrel body section; a syringe plunger configured to be mounted to the gasket and has an insertion section that can be inserted into the barrel body section; and an RFID tag mounted on the insertion section and including an antenna for communication and a memory.

The embodiments described herein may relate to methods and systems for adjusting insulin delivery. Some methods and systems may be configured to adjust insulin delivery to personalize automated insulin delivery for a person with diabetes. Such personalization may include adjusting user specific dosage parameters in response to a user provided insulin delivery amount, including a user provided insulin delivery amount that varies from a recommended insulin delivery amount. Methods and systems may include locking out automated modification of a baseline basal rate of insulin for the user for the time period after a user provides an insulin delivery amount.

The embodiments described herein may relate to methods and systems for adjusting insulin delivery. Some methods and systems may be configured to adjust insulin delivery to personalize automated insulin delivery for a person with diabetes. Such personalization may include adjusting user specific dosage parameters in response to a user provided insulin delivery amount, including a user provided insulin delivery amount that varies from a recommended insulin delivery amount.

Technologies are described for delivery of compounds to aid in weight management. A transdermal microdispenser based system may deliver weight management compounds through the time and dose specific administration of appetite suppression, metabolic enhancers, and satiation compounds. The transdermal delivery system may be controlled based on data associated with subject such as calorie intake, physical activity, satiation, and hunger. The system may be integrated with medical monitoring or fitness tracking systems. Delivery of the compounds may be distributed over the course of a day at selected or adjusted doses to be safe and effective for their specific modality. For example, appetite suppressants may be delivered during periods of the day when cravings occur, satiation compounds may be delivered to coincide with meals, and metabolic stimulators may be delivered at times to optimally increase metabolism based on caloric balance. Control factors may also be predictive to prevent the onset of hunger.